Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fasting Conditions

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Compare the rate and extent of absorption of famotidine 40 mg tablets, administered as 1 x 40 mg tablet under fasting conditions.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Perrigo Company
• Treatments: Famotidine

Criteria

Inclusion Criteria:

• healthy men or women 18 years of age or older

• body mass index below 30.0 kg/m2

• willing to participate and sin a copy of the informed consent form

Exclusion Criteria:

• recent history of drug or alcohol addiction or abuse

• pregnant or lactating women

• history of allergic response to heparin, famotidine, other H2-receptor antagonists, or other related drugs

• evidence of a clinically significant disorder or whose laboratory results were deemed to be clinically significant

• recipient of any drugs as part of a research study within 30 days prior to study dosing